Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxThe phase 3 DASL-HiCaP trial, presented at ESMO 2026, has demonstrated improved metastasis-free survival with the addition of darolutamide to androgen deprivation therapy (ADT) and radiotherapy in patients with localised or locally advanced prostate cancer at high risk of recurrence. The randomised, placebo-controlled study enrolled 1,106 patients, who received darolutamide or placebo alongside ADT and […]
UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide
/in Clinical Trial, Non-Metastatic, Phase 3/by MaxNew results from a randomised substudy of the phase 3 PROTEUS trial, presented at ESMO 2026, show that adding apalutamide and androgen deprivation therapy (ADT) before and after radical prostatectomy improves outcomes compared with surgery alone in patients with high-risk localised or locally advanced prostate cancer. The substudy enrolled 408 patients, including 102 receiving perioperative […]
UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNew phase 1/2 results published in the Journal of Clinical Oncology provide further evidence of the clinical activity of bavdegalutamide (ARV-110), an experimental androgen receptor (AR) degrader, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest that specific AR mutations may help identify patients most likely to benefit from this treatment. Unlike conventional […]
UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxUpdated results from the TheraPb phase 1 trial, presented at ESMO 2026, provide longer-term follow-up for ²¹²Pb-ADVC001, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). The study enrolled 22 heavily pretreated patients across different dose levels and treatment schedules. With an additional 12 months of observation and a median follow-up of […]
PEACE-1: Triplet Therapy Shows Lasting Survival Benefit at Eight Years
/in Clinical Trial, Metastatic, Phase 3/by MaxAfter a median follow-up of 7.7 years, the phase 3 PEACE-1 trial confirms a lasting survival benefit from adding abiraterone and prednisone to standard treatment for men diagnosed with metastatic hormone-sensitive prostate cancer. The trial enrolled 1,173 men and tested the addition of abiraterone, prostate radiotherapy, or both to androgen deprivation therapy (ADT), with or […]
UPDATE: JNJ-6143 Shows Early Activity in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdated phase 1 results provide further evidence of activity for JNJ-6143, previously known as HLD-0915 and also referred to as JNJ-101556143, in heavily pretreated metastatic castration-resistant prostate cancer. Following our previous coverage of its initial results and a separate phase 2 trial, the new findings add dose-specific outcomes and exploratory molecular data. JNJ-6143 is an […]
Phase 1 ProTACT: Actinium-225 FL-020 Shows Early Activity in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNew results show preliminary antitumor activity for 225Ac-FL-020, an investigational PSMA-targeted alpha radioligand, in patients with metastatic castration-resistant prostate cancer (mCRPC). The findings come from ProTACT, an ongoing first-in-human phase 1 trial evaluating the safety, dosing, and preliminary efficacy of FL-020 in patients previously treated with androgen receptor pathway inhibitors and taxane chemotherapy, unless chemotherapy […]
UPDATE: EIK1003 Plus Abiraterone Shows Early Activity in HRR-Mutated Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxNew results provide updated safety and efficacy data for EIK1003 (formerly IMP1734), an investigational selective PARP1 inhibitor, in combination with abiraterone and prednisone in patients with metastatic prostate cancer harboring homologous recombination repair (HRR) gene alterations. Unlike conventional PARP inhibitors, EIK1003 selectively targets PARP1 while largely sparing PARP2, potentially reducing the hematological toxicity associated with […]